PD501 - ACCEPTABILITY, ADHERENCE AND EXPLORATORY EFFECTS OF MICROBIAL PHYTASE SUPPLEMENTS ON IRON AND ZINC STATUS IN ADULTS WITH CHRONIC DISEASES: INTERIM ANALYSIS OF A RANDOMIZED OPEN-LABEL TRIAL
PD501
ACCEPTABILITY, ADHERENCE AND EXPLORATORY EFFECTS OF MICROBIAL PHYTASE SUPPLEMENTS ON IRON AND ZINC STATUS IN ADULTS WITH CHRONIC DISEASES: INTERIM ANALYSIS OF A RANDOMIZED OPEN-LABEL TRIAL
V. Svolos1,*, E. Zoupa1, A. Vlachou1, A. Triantafyllou1, G. Charmantzis1, D. E. Strongylou1, E. Dardiotis1, A. Samara1, M. Janho1, M.-N. Nanti1, D. Lygouras1, G. Raptis1, O. Androutsos1
1Department of Nutrition and Dietetics, School of Physical Education, Sport Science and Dietetics, University of Thessaly, Trikala, Greece
Rationale: Microbial phytase may improve iron and zinc bioavailability by degrading phytic acid, but human data in chronic disease populations remain limited. This interim analysis evaluates feasibility, adherence, safety and exploratory clinical effects.
Methods: In this randomized, controlled, open-label, parallel-group trial, adults with Crohn’s disease, ulcerative colitis, pre-hypertension, history of iron deficiency anaemia, or multiple sclerosis were assigned to two phytase-based supplements (Goodphyte IB Defense-microbial phytase plus probiotic; Goodphyte Immunity-microbial phytase plus iron and zinc) for 14 days (4 tablets/day). Stratified randomization was applied by diagnosis. Outcomes included adherence, acceptability, serum iron, ferritin, zinc, fatigue, health-related quality of life, disease-related symptoms, and faecal calprotectin in inflammatory bowel disease. Interim analyses were descriptive.
Results: Preliminary data were available for 43 participants (14 history of iron deficiency anaemia, 13 pre-hypertension, 8 inflammatory bowel disease, 8 multiple sclerosis); 11 remained on study and 1 withdrew (drop-out 2.3%). Adherence was high, with most participants consuming48–56/56 capsules during the 14-day intervention. No major tolerability concerns, disease deterioration, or safety signals were observed. Zinc levels remained stable. Exploratory trends suggested improvements in fatigue, quality of life and patient-reported disease activity, with signals of benefit for iron/ferritin and faecal calprotectin.
Conclusion: Short-term microbial phytase supplementation appears feasible, well tolerated and associated with high adherence in adults with chronic diseases. Potential benefits on fatigue, quality of life and iron-related and inflammatory markers require confirmation in the completed trial.
Disclosure of Interest: None declared